HERTFORDSHIRE, England, and PITTSBURGH, /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange Commission ("SEC"). On July 29, 2019, the Company disclosed in its public filings that it had reached an agreement-in-principle with the SEC's Division of Enforcement to settle the matter. The matter primarily concerns historical disclosures and accrual related to the U.S. Department of Justice's civil investigation concerning the classification of EpiPen® and EpiPen Jr® Auto-Injectors for purposes of the Medicaid Drug Rebate Program. Today's settlement fully resolves the SEC's investigation.  

Pursuant to the agreement with the SEC, Mylan neither admits nor denies the SEC's allegations, has consented to the entry of a final judgment, and will pay $30 million, which previously has been fully reserved. 

Mylan believes at this time, taking all other matters into consideration, that this settlement is the right course of action for the Company.  The Company continues to be committed to the highest levels of integrity with respect to all aspects of its business operations, including its public filing disclosures and communications with investors.

SOURCE Mylan N.V.